-
Mashup Score: 0Making the Switch in Atopic Dermatitis: Optimizing Treatment Targets With JAK Inhibitors - 19 minute(s) ago
Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD, discuss how Janus kinase (JAK) inhibitors are revolutionizing atopic dermatitis treatment by providing faster, deeper, and more durable responses than biologics, particularly for patients who haven’t achieved optimal treatment targets of simultaneous skin clearance and itch relief as defined by the AHEAD recommendations.
Source: www.hcplive.comCategories: General Medicine NewsTweet
-
Mashup Score: 2Hypercortisolism in Patients with Treatment-Resistant Type 2 Diabetes, with Richard Auchus, MD, PhD - 4 hour(s) ago
Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
We sat down with Richard Auchus, MD, PhD, to discuss his presentation at ENDO 2025 regarding the effects of hypercortisolism on type 2 diabetes and their combined risk to patients. Watch now: https://t.co/h3QqmiUVe1 https://t.co/mWuDfQBgaW
-
-
Mashup Score: 2Concurrent Lifestyle Intervention Enhances Semaglutide Weight Loss, with Qiaochu Xue, PhD, MPH - 5 hour(s) ago
Lifestyle intervention yielded greater maintained weight loss 12 months after discontinuing semaglutide than without.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
People with #obesity who engaged in lifestyle intervention while taking #semaglutide maintained weight loss 12 months after discontinuing semaglutide than those who didn't. Watch more now: https://t.co/PNDCwjAX0z @EmoryUniveristy https://t.co/GeBbjiVQcM
-
-
Mashup Score: 2
Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
In the latest episode of Liver Lineup, hosts @NancyReau and Kimberly Brown discuss major milestones enabling #HCV elimination efforts—and the critical gaps that continue to impede progress. 🎧 https://t.co/wOqqFqXQnW #HepatitisC #HCV #Hepatology #PublicHealth #Advocacy https://t.co/WeT2QRvGXM
-
-
Mashup Score: 0Brief CBT Eases Food Allergy Anxiety, With Marcus Shaker, MD - 8 hour(s) ago
Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Food allergy anxiety is real and often fueled by misconceptions. In this Q&A, Marcus Shaker, MD, @GeiselMed, shares how brief CBT & motivational interviewing can help shift patients’ mindset from fear to confidence. Read more: https://t.co/kYjkx0dFON https://t.co/xLc36ZvbZh
-
-
Mashup Score: 2
Capricor Therapeutics intends to resubmit a BLA for the potential first-in-class treatment with topline data from the ongoing HOPE-3 trial in Q3 2025.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
ICYMI: The #FDA recently issued a Complete Response Letter to Capricor for deramiocel, a cardiomyopathy treatment, citing a lack of substantial evidence and a need for further clinical data. Read more: https://t.co/h0qMvg41vk https://t.co/EaqtcxKma1
-
-
Mashup Score: 2HCPLive 5 Stories in Under 5: Week of 07/06 - 12 hour(s) ago
An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Listen to HCPLive's 5 Stories in Under 5 for a quick recap of last week's news, with exciting updates in #diabetes, #schizophrenia, and #PTSD. https://t.co/57LbtFzAYo https://t.co/00pLGyNE6v
-
-
Mashup Score: 2
Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
In the latest episode of Liver Lineup, hosts @NancyReau and Kimberly Brown discuss major milestones enabling #HCV elimination efforts—and the critical gaps that continue to impede progress. 🎧 https://t.co/DsrMc3gEt2 #HepatitisC #HCV #Hepatology #PublicHealth #Advocacy https://t.co/39k9RC7Hoa
-
-
Mashup Score: 2
This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Dual biologic therapy may be well-tolerated in treating refractory inflammatory skin conditions such as #psoriasis, new data suggest, although it carries a moderate risk of infection. View more: https://t.co/L9uV60ZLoE https://t.co/z8MCg5cp9e
-
-
Mashup Score: 2
This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Dual biologic therapy may be well-tolerated in treating refractory inflammatory skin conditions such as #psoriasis, new data suggest, although it carries a moderate risk of infection. View more: https://t.co/hJ6LjsVs47 https://t.co/zqb3I6bcpw
-
Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD, discuss how JAK inhibitors are reshaping AD treatment and offering faster, deeper, and more lasting relief than biologics. Watch Now: https://t.co/CRS9JdcqjW https://t.co/WtQMG8sEc9